Becton Dickinson And Company Stock News

Should investors be excited or worried when a stock crosses above the 20-day simple moving average?

Becton, Dickinson And Co. (BDX) shares closed 0.8% higher than its previous 52 week high, giving the company a market cap of $73B. The stock is currently up 2.1% year-to-date, up 0.8% over the past 12 months, and up 53.7% over the past five years. This week, the Dow Jones Industrial Average rose 4.3%, and the S&P 500 rose 5.5%. Trading Activity Trading volume this week was 8.0% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.2. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -125.5% The company's stock price performance over the past 12 months lags the peer average by -91.1% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is -35.7% lower than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

It was another bad day for the market, but these companies are looking strong.

The majority of BD's (BDX) core units witness strong revenue growth in the fiscal first quarter.

Becton, Dickinson and Company (BDX) CEO Thomas Polen on Q1 2022 Results - Earnings Call Transcript

Becton Dickinson Earnings, Revenue Beat in Q1

Becton, Dickinson press release (BDX): Q1 Non-GAAP EPS of $3.64 beats by $0.79.Revenue of $5B (-6.0% Y/Y) beats by $240M.The company raised its full year revenue and adjusted

Becton Dickinson and Co BDX reported Q1 FY22 revenues of $4.9 billion, down 6% Y/Y (-5.9% on a currency-neutral basis), better than the consensus of $4.76 billion. Get the Inside Access Traders Are U

Becton Dickinson (BDX) delivered earnings and revenue surprises of 27.27% and 4.65%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Becton, Dickinson and Company (BDX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Becton, Dickinson and Company''s (BDX) board approved the spinoff of its diabetes care business, which will be known as Embecta, and declared a pro rata distribution of Embecta shares of

Becton, Dickinson and Co (NYSE: BDX ) has acquired Cytognos , a unit of Vitro SA , a Spanish diagnostics company that develops, produces, and sells fully integrated reagents, hardware, and software platforms. Deal terms were not disclosed . Cytognos specializes in flow cytometry solutions for blood cancer diagnosis, minimal residual disease (MRD) detection, and immune … Full story available on Benzinga.com

Becton, Dickinson and Co (NYSE: BDX) has acquired Cytognos, a unit of Vitro SA, a Spanish diagnostics company that develops, produces, and sells fully integrated reagents, hardware, and software pl

Continued strength in BD's (BDX) Life Sciences and Interventional segments is expected to have driven up Q1 sales.